SCHEMBL6026883

SCHEMBL6026883

C=CC(=O)Oc1c(F)cccc1OC

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.51
KRAS P01116 2/20 0.43
NFE2L2 Q16236 4/20 0.42
SLC2A1 P11166 1/20 0.41
SLC2A4 P14672 1/20 0.41
NPC1 O15118 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
THRA P10827 1/20 0.40
THRB P10828 1/20 0.40
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA7 P43166 1/20 0.40
CA9 Q16790 1/20 0.40
CA14 Q9ULX7 1/20 0.40
KDM4E B2RXH2 2/20 0.38
LMNA P02545 1/20 0.38
HPGD P15428 1/20 0.38
MEN1 O00255 1/20 0.38
FFAR4 Q5NUL3 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24810564 0.89 NFE2L2 (0.47) KMT2ANFE2L2NPC1SMN1; SMN2THRA
SCHEMBL5690942 0.85 KMT2A (0.41) KMT2AKRASSLC2A1SLC2A4NPC1
SCHEMBL6653138 0.83 TP53 (0.47) KMT2ANFE2L2NPC1THRATHRB
SCHEMBL28714121 0.82 NFE2L2 (0.53) NFE2L2THRATHRBCA12CA1
SCHEMBL15239366 0.81 MEN1 (0.43) KMT2ANFE2L2THRATHRBCA12
SCHEMBL28133169 0.81 KDM4E (0.39) KMT2ASLC2A1SLC2A4SMN1; SMN2THRA
SCHEMBL21708685 0.80 KMT2A (0.56) KMT2AKRASNFE2L2SLC2A1SLC2A4
SCHEMBL12473728 0.80 THRB (0.40) KMT2AKRASTHRATHRB
SCHEMBL28326387 0.80 MAPK1 (0.54) KMT2ANFE2L2NPC1CA12CA1
SCHEMBL24810562 0.80 SRC (0.56) KMT2ANFE2L2NPC1CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116768792-A Cinnamamide-hydroxypyridone derivative, and preparation method and application thereof 浙江工业大学 2023-09-19 CN disclosed
EP-2595952-B1 AGONISTS OF GPR40 CONNEXIOS LIFE SCIENCES PVT LTD (IN) 2020-11-18 EP disclosed
US-9278915-B2 Agonists of GPR40 CONNEXIOS LIFE SCIENCES PVT LTD (IN) 2016-03-08 US disclosed
US-20130237571-A1 AGONISTS OF GPR40 Conexios Life Sciences PVT. LTD. (IN) 2013-09-12 US disclosed
EP-1697339-A1 3-(4-BENZYLOXYPHENYL)PROPANOIC ACID DERIVATIVES Takeda Pharmaceutical Company Limited (JP) 2006-09-06 EP disclosed
WO-2005063729-A1 3-(4-BENZYLOXYPHENYL)PROPANOIC ACID DERIVATIVES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-07-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130237571-A1 AGONISTS OF GPR40 GPR65, GPR55, GPR68 KMT2A 3880/4885KRAS 2982/4885NFE2L2 2685/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.